| Neoadjuvant PD-1 blockade in resectable lung cancer PM Forde, JE Chaft, KN Smith, V Anagnostou, TR Cottrell, MD Hellmann, ... New England Journal of Medicine 378 (21), 1976-1986, 2018 | 2102 | 2018 |
| Direct detection of early-stage cancers using circulating tumor DNA J Phallen, M Sausen, V Adleff, A Leal, C Hruban, J White, V Anagnostou, ... Science translational medicine 9 (403), eaan2415, 2017 | 1136 | 2017 |
| Genome-wide cell-free DNA fragmentation in patients with cancer S Cristiano, A Leal, J Phallen, J Fiksel, V Adleff, DC Bruhm, SŲ Jensen, ... Nature 570 (7761), 385-389, 2019 | 1055 | 2019 |
| Programmed death ligand-1 expression in non-small cell lung cancer V Velcheti, KA Schalper, DE Carvajal, VK Anagnostou, KN Syrigos, ... Laboratory investigation 94 (1), 107-116, 2014 | 946 | 2014 |
| Evolution of neoantigen landscape during immune checkpoint blockade in non–small cell lung cancer V Anagnostou, KN Smith, PM Forde, N Niknafs, R Bhattacharya, J White, ... Cancer discovery 7 (3), 264-276, 2017 | 903 | 2017 |
| Antibody validation J Bordeaux, AW Welsh, S Agarwal, E Killiam, MT Baquero, JA Hanna, ... Biotechniques 48 (3), 197-209, 2010 | 792 | 2010 |
| Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients M Sausen, J Phallen, V Adleff, S Jones, RJ Leary, MT Barrett, ... Nature communications 6 (1), 7686, 2015 | 492 | 2015 |
| Personalized genomic analyses for cancer mutation discovery and interpretation S Jones, V Anagnostou, K Lytle, S Parpart-Li, M Nesselbush, DR Riley, ... Science translational medicine 7 (283), 283ra53-283ra53, 2015 | 492 | 2015 |
| The genomic landscape of response to EGFR blockade in colorectal cancer A Bertotti, E Papp, S Jones, V Adleff, V Anagnostou, B Lupo, M Sausen, ... Nature 526 (7572), 263-267, 2015 | 491 | 2015 |
| Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer MJ Topper, M Vaz, KB Chiappinelli, CEDS Shields, N Niknafs, RWC Yen, ... Cell 171 (6), 1284-1300. e21, 2017 | 457 | 2017 |
| Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) TR Cottrell, ED Thompson, PM Forde, JE Stein, AS Duffield, ... Annals of Oncology 29 (8), 1853-1860, 2018 | 446 | 2018 |
| GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer KL Scott, O Kabbarah, MC Liang, E Ivanova, V Anagnostou, J Wu, ... Nature 459 (7250), 1085-1090, 2009 | 421 | 2009 |
| Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers JX Caushi, J Zhang, Z Ji, A Vaghasia, B Zhang, EHC Hsiue, BJ Mog, ... Nature 596 (7870), 126-132, 2021 | 378 | 2021 |
| Detection and characterization of lung cancer using cell-free DNA fragmentomes D Mathios, JS Johansen, S Cristiano, JE Medina, J Phallen, KR Larsen, ... Nature communications 12 (1), 5060, 2021 | 320 | 2021 |
| Conserved interferon-γ signaling drives clinical response to immune checkpoint blockade therapy in melanoma CS Grasso, J Tsoi, M Onyshchenko, G Abril-Rodriguez, ... Cancer cell 38 (4), 500-515. e3, 2020 | 320 | 2020 |
| Dynamics of tumor and immune responses during immune checkpoint blockade in non–small cell lung cancer V Anagnostou, PM Forde, JR White, N Niknafs, C Hruban, J Naidoo, ... Cancer research 79 (6), 1214-1225, 2019 | 290 | 2019 |
| Cancer immunotherapy: a future paradigm shift in the treatment of non–small cell lung cancer VK Anagnostou, JR Brahmer Clinical Cancer Research 21 (5), 976-984, 2015 | 285 | 2015 |
| Association of high tumor mutation burden in non–small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 … B Ricciuti, X Wang, JV Alessi, H Rizvi, NR Mahadevan, YY Li, A Polio, ... JAMA oncology 8 (8), 1160-1168, 2022 | 225 | 2022 |
| White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer A Leal, NCT van Grieken, DN Palsgrove, J Phallen, JE Medina, C Hruban, ... Nature communications 11 (1), 525, 2020 | 221 | 2020 |
| Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor–positive metastatic breast cancer: a randomized phase II study CK Osborne, P Neven, LY Dirix, JR Mackey, J Robert, C Underhill, ... Clinical Cancer Research 17 (5), 1147-1159, 2011 | 195 | 2011 |
Victor VelculescuProfessor of Oncology, Johns Hopkins University School of MedicineVerified email at jhmi.edu
